发明申请
US20130045188A1 REDUCTION OF TGF BETA SIGNALING IN MYELOID CELLS IN THE TREATMENT OF CANCER
有权
减少糖尿病细胞中TGFββ信号在癌症治疗中的作用
- 专利标题： REDUCTION OF TGF BETA SIGNALING IN MYELOID CELLS IN THE TREATMENT OF CANCER
- 专利标题（中）： 减少糖尿病细胞中TGFββ信号在癌症治疗中的作用
-
申请号： US13589769申请日： 2012-08-20
-
公开(公告)号： US20130045188A1公开(公告)日： 2013-02-21
- 发明人: Li Yang
- 申请人： Li Yang
- 申请人地址： US MD Bethesda
- 专利权人： The United States of America, as represented by the Secretary, Dept. of Health and Human Services
- 当前专利权人： The United States of America, as represented by the Secretary, Dept. of Health and Human Services
- 当前专利权人地址： US MD Bethesda
- 主分类号： A61K31/7088
- IPC分类号： A61K31/7088 ; A61K35/12 ; C12N15/85 ; C12N1/19 ; C12Q1/68 ; A61P35/04 ; C12N15/86 ; C40B30/00 ; G01N33/566 ; A61M37/00 ; C12N5/071 ; A61K31/5377 ; B82Y5/00
摘要：
Methods of inhibiting metastasis in cancer patients are provided, wherein the methods comprise reducing TGFβ signaling, for example, by reducing TGF receptor II expression in myeloid cells. Vectors comprising a TGFβ receptor II RNAi nucleic acid sequence operably linked to a myeloid specific promoter also are provided. A method of diagnosing cancer in an individual by determining TGFβ receptor II expression in myeloid cells in the individual is provided. Additionally, a method of modulating TGFβ activity in myeloid cells in a cancer patient comprising administering a regulator of at least one of the GSK3 and PI3K pathways to the patient is provided.
公开/授权文献
信息查询
